Determining The Risk of Cardio- and Vasotoxicity of Antitumor Therapy: to Whom, When, Why?
Open Access
- 31 January 2025
- journal article
- review article
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (1) , 3-10
Abstract
It is known that the advances in cancer treatment leading to increased survival in malignant neoplasms, entail a variety of adverse cardiovascular toxic effects that can be quite serious and even potentially fatal. An important component that influences the degree of cardiotoxicity risk is the patient’s clinical and functional state and the cardiovascular history at the time of cancer diagnosis. This information can be used in practice for the cardiovascular screening and clinical and functional evaluation of a patient with a neoplasm before the start of antitumor therapy. After completion of the cardiotoxic therapy, as well as during subsequent follow-up, it is advisable to re-evaluate the risk of long-term cardiotoxicity to determine the frequency and intensity of cardiovascular monitoring. For convenience of calculating the risk of cardiotoxicity in cancer patients undergoing the antitumor treatment, the authors of this article have developed two computer programs that can be used as PC applications (https://disk.yandex.ru/d/NuhzYnicWo9FSw) and on mobile devices (https://disk.yandex.ru/d/uXAriKZ6qhkULA.). These programs facilitate the selection of the correct strategy for the management of cancer patients that is aimed at reducing the likelihood of cardiotoxic complications of the antitumor treatment.Keywords
This publication has 12 references indexed in Scilit:
- Guidance letter for cardiologists of oncology institutions on the prevention of cardiovascular complications of anticancer therapy. Interdisciplinary Council of Cardio-Oncology, Russian Society of CardiologyCardiovascular Therapy and Prevention, 2023
- Guidance letter for cardiologists and primary care physicians on primary prevention of cardiovascular complications of anticancer therapy. Interdisciplinary Council of Cardio-Oncology, Russian Society of CardiologyCardiovascular Therapy and Prevention, 2023
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)European Heart Journal - Cardiovascular Imaging, 2022
- Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesCirculation, 2022
- Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapyRussian Journal of Cardiology, 2021
- Specialized electronic questionnaires of radiation therapy outcomes and quality of cancer patient's lifeMedical doctor and information technologies, 2021
- Cardiotoxic effects and myocardial injury: the search for a more precise definition of drug cardiotoxicityClinical Chemistry and Laboratory Medicine (CCLM), 2020
- Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyEuropean Journal of Heart Failure, 2020
- Cardio-oncology: what you need to know now for clinical practice and echocardiographyEcho Research & Practice, 2017
- Measurement equivalence and feasibility of the EORTC QLQ-PR25: paper-and-pencil versus touch-screen administrationHealth and Quality of Life Outcomes, 2014